EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Marine and algae Sources: 7

Fucoidan

Also called: sulfated alpha-L-fucan, fucoidin, fucan, mekabu fucoidan

Fucoidan is a sulfated polysaccharide found in the cell walls of many species of brown seaweed. It is sold as capsules, extracts and powder; in the EU, fucoidan extracts from Fucus vesiculosus and Undaria pinnatifida are authorized novel foods.

Category
Marine and algae
Forms
Extracts of brown seaweeds (e.g., Fucus vesiculosus, Undaria pinnatifida); high- and low-molecular-weight forms
Strongest evidence
C Limited
Reviewed
2026-10-28

Class 2 Moderately studied in people. No review stating a count of single-ingredient RCTs was found. This entry cites 4 RCTs of oral fucoidan alone: sources 2-5, versus placebo, 30 to 95 participants; two added fucoidan to cancer treatment. A 2026 systematic review (source 6) found 3 RCTs and 2 open-label studies. [2]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

6 topics studied5 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Fucoidan does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Fucoidan, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Urinary symptoms in benign prostatic hyperplasiaCRCT in 95 men aged 45–80 with moderate BPH: Undaria pinnatifida fucoidan for 90 days reduced symptom scores (IPSS −3.40 vs −0.93 with placebo); urine flow, residual volume and PSA did not differ. [2]
Blood sugar in type 2 diabetesCCrossover RCT in 30 patients: 1,620 mg/day for 12 weeks increased stool frequency; HbA1c fell slightly (6.73% to 6.59%) only in a subgroup of 14 without insulin resistance. [3]
Blood pressure and LDL cholesterol in overweight adultsCIn overweight or obese adults, fucoidan for 3 months decreased diastolic blood pressure and LDL cholesterol and increased insulin secretion (studies summarized by MSK). [1]
Quality of life during rectal cancer chemoradiotherapyCRCT in 87 patients: low-molecular-weight fucoidan improved physical well-being and reduced rash, itching and fatigue, but the overall colorectal quality-of-life score did not differ significantly. [4]
Tumor control with chemoembolization in liver cancerCRCT in 82 patients with unresectable hepatocellular carcinoma: low-molecular-weight fucoidan with TACE for 6 months raised disease control (95.24% vs 80.00%); objective response did not differ significantly. [5]
Inflammation and immune measuresC2026 systematic review of 5 clinical studies: some trials reported lower inflammatory cytokines or NK-cell changes, but findings were not consistently replicated; evidence is limited and heterogeneous. [6]

Main constituents: Sulfated alpha-L-fucan (sulfated polysaccharide) [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 1,620 mg/day in a beverage for 12 weeks (type 2 diabetes trial). [3]
  • Low-molecular-weight fucoidan 4.4 g twice daily for 6 months (liver cancer trial). [5]

Upper limits

  • EU: fucoidan extracts from Fucus vesiculosus or Undaria pinnatifida are authorized in foods, including food supplements, at up to 250 mg/day. [7]
Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    2 listed

    Anticoagulants such as warfarin and heparin; Letrozole and tamoxifen

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    EU Union list of novel foods (Commission Implementing Regulation (EU) 2017/2470, original text): fucoidan extract from Fucus vesiculosus or from …

    Details and sources
  • Oral fucoidan was generally well tolerated in clinical studies, with no serious adverse events reported. [6]
  • Diarrhea, which improved immediately after stopping, was reported in a small study. Fucoidan has anticoagulant and antithrombotic activity. [1]
Interactions

Interactions

Fucoidan
From the table below 2 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Fucoidan
WithWhat happens
Anticoagulants such as warfarin and heparinBecause of its antithrombotic effects, fucoidan may increase bleeding risk. [1]
Letrozole and tamoxifenIn a small study of breast cancer patients, co-administration was well tolerated without clinically significant interactions. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • The 2026 review cited heterogeneity in fucoidan characteristics and study populations as reasons definitive conclusions are not possible. Products include high- and low-molecular-weight fucoidans. [6]
Regulation

Regulatory status

  • EU: in the Union list of novel foods; labels must read 'Fucoidan extract from seaweed Fucus vesiculosus' or 'Fucoidan extract from seaweed Undaria pinnatifida'. [7]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Fucoidan (sulfated alpha-L-fucan): a sulfated polysaccharide found in the cell walls of many species of brown seaweed; MSK discusses both high- and low-molecular-weight fucoidans Polysaccharides (sulfated) [P5]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming fucoidan (earliest NDI 91 submitted 2000-08-17; most recent NDI 118 submitted 2001-07-16). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of fucoidan was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P2]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of fucoidan (checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Anticoagulants such as warfarin and heparin: Because of its antithrombotic effects, fucoidan may increase bleeding risk. [P5]
  • Letrozole and tamoxifen: In a small study of breast cancer patients, co-administration was well tolerated without clinically significant interactions. [P5]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]

Supply and conservation

  • Fucoidan is obtained from brown seaweeds; the EU novel-food authorizations name extracts from Fucus vesiculosus and Undaria pinnatifida. [P7]

Absorption in people

  • Using a fucoidan-specific sandwich ELISA in 10 healthy volunteers, fucoidan (from Cladosiphon okamuranus) was not detected before dosing and serum and urine levels rose markedly 6 and 9 h after oral administration; serum fucoidan kept its molecular weight, while urinary fucoidan was of lower molecular weight. [P6]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU Union list of novel foods (Commission Implementing Regulation (EU) 2017/2470, original text): fucoidan extract from Fucus vesiculosus or from Undaria pinnatifida is authorized in foods including food supplements for the general population at a maximum of 250 mg/day. [P7]

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  3. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-29. ntp.niehs.nih.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. Memorial Sloan Kettering Cancer Center. About Herbs: Fucoidan (last updated May 14, 2026), 2026-05-14. mskcc.org
  6. Tokita Y, et al. Development of a fucoidan-specific antibody and measurement of fucoidan in serum and urine by sandwich ELISA. Biosci Biotechnol Biochem 2010;74(2):350-357 (PMID 20139614), 2010-02. pubmed.ncbi.nlm.nih.gov
  7. Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods (original text, OJ L 351, 30.12.2017), 2017-12-20. eur-lex.europa.eu
Sources

Sources

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Fucoidan (last updated May 14, 2026), 2026-05-14. mskcc.org
  2. Wimmer BC, et al. Fucoidan from Undaria pinnatifida improves benign prostatic hyperplasia symptoms in men: a randomized, double-blind, placebo-controlled study. Res Rep Urol 2026;18:597883, 2026-07-15. pubmed.ncbi.nlm.nih.gov
  3. Sakai C, et al. A randomized placebo-controlled trial of an oral preparation of high molecular weight fucoidan in patients with type 2 diabetes with evaluation of taste sensitivity. Yonago Acta Med 2019;62(1):14-23, 2019-03-28. pubmed.ncbi.nlm.nih.gov
  4. Tsai HL, et al. The auxiliary effects of low-molecular-weight fucoidan in locally advanced rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy before surgery: a double-blind, randomized, placebo-controlled study. Integr Cancer Ther 2023;22, 2023. pubmed.ncbi.nlm.nih.gov
  5. Zou Y, et al. Fucoidan improves tumor control and liver function in TACE for unresectable hepatocellular carcinoma: a randomised trial. Liver Int 2025;45(10):e70347, 2025-10. pubmed.ncbi.nlm.nih.gov
  6. Anari ES, et al. Fucoidan as an anti-inflammatory and immunomodulatory agent in humans: a systematic review of clinical evidence and translational potential. Food Funct 2026 (online ahead of print), 2026-09-29. pubmed.ncbi.nlm.nih.gov
  7. Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods (original text), 2017-12-20. eur-lex.europa.eu
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in marine and algae: Astaxanthin · Bladderwrack · Carrageenan and agar · Chlorella · Dunaliella · Ecklonia cava · Kelp and seaweed · Sea moss · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.